Metyrapone is a competitive inhibitor of 11β-hydroxysteroid dehydrogenase type 1 reductase
- 30 June 1997
- journal article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 62 (2-3) , 195-199
- https://doi.org/10.1016/s0960-0760(97)00027-7
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Extra‐adrenal effects of metyrapone include inhibition of the 11‐oxoreductase activity of 11β‐hydroxysteroid dehydrogenase: a model for 11‐HSD I deficiencyClinical Endocrinology, 1995
- Treatment of Major Depression with metyrapone and hydrocortisoneJournal of Affective Disorders, 1995
- 11β-Hydroxysteroid DehydrogenasePublished by Elsevier ,1993
- Treatment of major depression with steroid suppressive drugsThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- In VivoAdrenocorticotropin (1-24)-Induced Accumulation of Cyclic Adenosine Monophosphate by Ovine Fetal Adrenal Cells Is Inhibited by Concomitant Infusin of Metopirone*Endocrinology, 1984
- Dual Sites of Inhibition by Metyrapone of Human Adrenal Steroidogenesis: Correlation ofin Vivoand andin VitroStudiesJournal of Clinical Endocrinology & Metabolism, 1976
- Experience with a rapid oral metyrapone test and the plasma ACTH content in determining the cause of Cushing's syndromeMetabolism, 1969
- Crystallization of ChlorophyllsScience, 1958
- ALTERATIONS OF ADRENAL STEROID PATTERNS IN MAN RESULTING FROM TREATMENT WITH A CHEMICAL INHIBITOR OF 11 βHYDROXYLATIONJournal of Clinical Endocrinology & Metabolism, 1958
- New Amphenone analogs as adrenocortical inhibitorsCellular and Molecular Life Sciences, 1958